Antiplatelet drug: mechanisms, uses, and clinical considerations

How they work and principal classes

Antiplatelet agents act by interfering with platelet activation, signaling, or the final aggregation step. Major drug classes include:

• COX inhibitors (for example, low‑dose aspirin) that block thromboxane A2 production and reduce platelet activation.
• P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) that prevent ADP‑mediated platelet activation.
• Glycoprotein IIb/IIIa inhibitors used intravenously in high‑risk acute coronary settings to prevent fibrinogen binding and aggregation.
• Other agents such as dipyridamole, which increases cyclic nucleotides and has vasodilatory effects.

Clinical uses and examples

Antiplatelet drugs are commonly prescribed for secondary prevention after myocardial infarction or ischemic stroke, for people with established coronary artery disease, and to reduce thrombotic risk after stent placement. In some patients with peripheral arterial disease they lower the risk of arterial events. Typical examples are aspirin and clopidogrel; combination regimens are used for defined periods after certain procedures.

Distinctions, risks, and practical points

Antiplatelet agents differ from anticoagulants, which target the coagulation cascade and are particularly effective against venous clots. Antiplatelets are most useful for preventing arterial thrombosis. The main adverse effect is bleeding, most often mucosal or gastrointestinal; serious hemorrhage is a recognized risk and must be balanced against benefit. Drug choice, dose, and duration depend on the clinical situation and bleeding risk.

History and notable facts

Aspirin was among the first widely used antiplatelet agents and remains inexpensive and broadly available. Newer agents expanded options for higher‑risk patients or those intolerant to older drugs. Clinical guidelines guide the appropriate selection and combination of antiplatelet and anticoagulant therapies to reduce thrombotic complications while managing bleeding risk. For further reading see platelet biology and guideline summaries at professional sources or educational materials referenced by clinicians (blood disorders, stroke care, cardiac care).